Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cancer Antigen 125 (CA125), also known as MUC16, is a high molecular weight glycoprotein and a member of the mucin family. It is involved in cell adhesion, tumor proliferation, metastasis, and immune modulation. Elevated serum levels are associated with epithelial ovarian cancer and are used for monitoring disease progression and response to therapy. It is an emerging target for antibody-mediated immunotherapy.
Antibody-mediated immunotherapy targeting epitopes within SEA domain
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer Antigen 125 (CA125/MUC16).